WASHINGTON, Nov. 13 -- Humira (adalimumab) has a "quite profound" benefit for children with juvenile rheumatoid arthritis and is well-tolerated, a researcher reported here.
The finding was based on a prospective 48-week clinical trial and 88 weeks of an extension study, according to Daniel Lovell, M.D., of the Cincinnati Children's Hospital Medical Center. The results mean "we can now make the disease almost a non-issue" for children.
Some benefit was expected, because the drug is approved for rheumatoid arthritis in adults, but the magnitude and speed of action was a surprise, Dr. Lovell told a press conference at the American College of Rheumatology meeting.
He said more than one in five children in the study "for the first time ever" achieved a benefit of ACR Ped 90 - meaning that of six elements of the disease deemed important for children by the ACR, at least three improved by more than 90%.